CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
100 mg twice daily (bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be e...
Phase 3
Whittier, California, United States and 108 other locations
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries. The purpose of this study is...
Phase 1
Duarte, California, United States and 11 other locations
objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic...
Phase 3
Los Angeles, California, United States of America and 111 other locations
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing o...
Phase 2
Whittier, California, United States and 67 other locations
The purpose of this study is to compare the efficacy and safety of pirtobrutinib (LOXO-305; Arm A) compared to BR (Arm B) in patients with CLL/SLL wh...
Phase 3
Los Angeles, California, United States and 107 other locations
This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic...
Phase 3
Los Angeles, California, United States and 130 other locations
The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants...
Phase 3
Cerritos, California, United States of America and 179 other locations
) and prednisone).The study includes patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)/small lymphocytic...
Phase 1, Phase 2
Los Angeles, California, United States and 75 other locations
of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic...
Phase 3
Long Beach, California, United States and 47 other locations
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL...
Phase 1, Phase 2
Los Angeles, California, United States and 79 other locations
Clinical trials
Research sites
Resources
Legal